Global Interventional Oncology Devices Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Product;
Embolization Devices, Ablation Devices, and Support Devices.By Procedure;
Thermal Tumor Ablation, Non-thermal Tumor Ablation, Transcatheter Arterial Chemoembolization (TACE), Transcatheter Arterial Radioembolization (TARE), or Selective Internal Radiation Therapy (SIRT), and Transcatheter Arterial Embolization (TAE), or Bland Embolization.By Cancer Type;
Liver Cancer, Kidney Cancer, Lung Cancer, Bone Cancer, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Interventional Oncology Devices Market (USD Million), 2021 - 2031
In the year 2024, the Global Interventional Oncology Devices Market was valued at USD 2,424.99 million. The size of this market is expected to increase to USD 4,577.29 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 9.5%.
The Global Interventional Oncology Devices Market encompasses a broad spectrum of medical devices and equipment utilized in the diagnosis, treatment, and management of various cancers through minimally invasive procedures. This market is experiencing robust growth driven by several factors, including technological advancements, increasing cancer incidence, and a shift towards minimally invasive treatment modalities.
Interventional oncology procedures involve the use of specialized devices such as radiofrequency ablation (RFA) devices, microwave ablation devices, cryoablation devices, and transarterial chemoembolization (TACE) systems, among others, to target and destroy cancerous tumors. These devices offer patients less invasive alternatives to traditional surgery, with benefits such as reduced recovery times, fewer complications, and improved quality of life.
One of the key drivers of market growth is the rising incidence of cancer worldwide. As cancer rates continue to climb, there is a growing need for effective and less invasive treatment options that can be delivered with precision. Additionally, technological advancements in interventional oncology devices, such as improved imaging modalities and navigation systems, are enhancing the accuracy and safety of cancer treatments, further driving market expansion.
Geographically, North America and Europe currently dominate the interventional oncology devices market, owing to factors such as well-established healthcare infrastructure, high adoption rates of advanced medical technologies, and increasing investment in cancer research and treatment. However, emerging markets in Asia-Pacific and Latin America are also witnessing rapid growth, fueled by expanding healthcare infrastructure, rising healthcare expenditure, and growing awareness about the benefits of minimally invasive cancer treatments.
The Global Interventional Oncology Devices Market is poised for continued growth as technological innovation continues to drive the development of more advanced and effective devices, and as healthcare systems worldwide increasingly recognize the value of minimally invasive approaches in cancer care.
Global Interventional Oncology Devices Market Recent Developments
-
In August 2022, Boston Scientific Corporation acquired Obsidio, Inc. This acquisition strengthens the company’s interventional oncology & embolization portfolio with the addition of Gel Embolic Material (GEM) technology, offering a differentiated solution to patients and physicians.
-
In July 2021, Terumo Europe announced the signing of a Memorandum of Understanding (MoU) with the University Medical Center Utrecht (UMC Utrecht) to extend their partnership and enhance education and innovations for the development of effective solutions in interventional oncology.
Segment Analysis
The interventional oncology market offers a variety of products, including embolization devices, ablation devices, and support devices, which are used to treat various types of cancer. Embolization devices are employed to block or reduce blood flow to tumors, effectively depriving them of nutrients and causing tumor shrinkage. Ablation devices, which can use thermal or non-thermal methods, are used to destroy cancerous tissue by applying heat or cold. Support devices, such as catheters and guidewires, assist in the delivery and placement of these treatment devices, ensuring accuracy and minimizing complications during procedures. These devices are key to minimally invasive cancer treatments that offer an alternative to traditional surgery.
The procedures associated with these devices include thermal and non-thermal tumor ablation, along with several types of embolization therapies. Thermal tumor ablation uses heat to destroy cancer cells, commonly through radiofrequency or microwave methods. Non-thermal ablation, on the other hand, typically utilizes cryoablation, which involves freezing the tumor to induce cell death. Transcatheter arterial chemoembolization (TACE) and transcatheter arterial radioembolization (TARE), also known as selective internal radiation therapy (SIRT), are techniques that combine embolization with chemotherapy or radiation to target tumors more precisely. Transcatheter arterial embolization (TAE) or bland embolization, another form of embolization, blocks the blood supply to tumors without the use of chemotherapy or radiation.
The treatment of various cancer types is a major driver of the interventional oncology market, with liver cancer, kidney cancer, lung cancer, and bone cancer being common targets for these procedures. Liver cancer, in particular, benefits from embolization and ablation therapies due to the liver’s unique blood supply and the ability to selectively target tumors. Kidney cancer can also be treated effectively with thermal ablation and embolization techniques, especially in cases where surgical options are limited. Lung cancer treatments often focus on advanced-stage tumors, where embolization or ablation can help manage symptoms and slow disease progression. Bone cancer, often associated with metastasis, can be treated with localized therapies to reduce pain and prevent further bone damage. Each cancer type requires customized treatment strategies, with interventional oncology providing effective options for patients who may not be candidates for traditional surgery.
Global Interventional Oncology Devices Segment Analysis
In this report, the Global Interventional Oncology Devices Market has been segmented by Product, Procedure, Cancer Type and Geography.
Global Interventional Oncology Devices Market, Segmentation by Product
In this report, the Global Interventional Oncology Devices Market has been segmented by Product into Embolization Devices, Ablation Devices and Support Devices.
Embolization Devices play a crucial role in interventional oncology procedures by blocking or reducing blood flow to tumors, thereby depriving them of oxygen and nutrients essential for their growth. These devices include microspheres, coils, and particles, which are precisely delivered to the tumor site via catheters. Embolization procedures are commonly used to treat liver cancer, uterine fibroids, and other malignancies, offering patients a minimally invasive alternative to surgery.
Ablation Devices are another integral component of interventional oncology, designed to destroy cancerous tissue through various energy-based modalities such as radiofrequency, microwave, or cryoablation. These devices deliver controlled thermal or freezing energy to the tumor, causing cell death and tumor shrinkage. Ablation procedures are commonly used for treating small tumors or lesions in organs such as the liver, kidney, lung, and bone. They are favored for their precision, minimal invasiveness, and ability to preserve healthy surrounding tissue, making them suitable for patients who are not candidates for surgery or other treatments.
Support Devices encompass a range of tools and accessories used to facilitate interventional oncology procedures, including catheters, guidewires, drainage systems, and imaging equipment. These devices are essential for guiding interventional radiologists during procedures, ensuring accurate placement of embolization or ablation devices, and monitoring patient response in real-time. Support devices play a critical role in enhancing procedural efficacy, safety, and patient outcomes, contributing to the overall success of interventional oncology treatments. As the demand for minimally invasive cancer therapies continues to rise, the market for interventional oncology devices, including embolization, ablation, and support devices, is expected to expand significantly, driven by technological advancements and increasing adoption of interventional oncology procedures worldwide.
Global Interventional Oncology Devices Market, Segmentation by Procedure
In this report, the Global Interventional Oncology Devices Market has been segmented by Procedure into Thermal Tumor Ablation, Non-thermal Tumor Ablation, Transcatheter Arterial Chemoembolization (TACE), Transcatheter Arterial Radioembolization (TARE) or Selective Internal Radiation Therapy (SIRT) and Transcatheter Arterial Embolization (TAE) or Bland Embolization.
Thermal Tumor Ablation involves the use of heat-based energy sources such as radiofrequency ablation (RFA) or microwave ablation to destroy cancerous tissue. These procedures are effective for treating small to medium-sized tumors in various organs, offering patients a minimally invasive alternative to surgery with reduced recovery times and fewer complications. Non-thermal Tumor Ablation encompasses techniques such as cryoablation, irreversible electroporation (IRE), and high-intensity focused ultrasound (HIFU), which utilize non-thermal energy sources to induce cell death in tumors. These procedures are particularly suitable for tumors located near sensitive structures or in regions where thermal ablation may be challenging, providing precise and targeted treatment with minimal damage to surrounding healthy tissue. Transcatheter Arterial Chemoembolization (TACE) involves the delivery of chemotherapy drugs directly to the tumor site via catheter, followed by the embolization of blood vessels to restrict blood flow to the tumor. TACE is commonly used to treat liver cancer and hepatic metastases, offering a localized and targeted approach to chemotherapy delivery while minimizing systemic side effects.
Transcatheter Arterial Radioembolization (TARE), also known as Selective Internal Radiation Therapy (SIRT), involves the delivery of radioactive microspheres directly into the blood vessels supplying the tumor. These microspheres emit radiation locally, targeting the tumor while sparing healthy surrounding tissue. TARE is primarily used for treating liver cancer and metastatic colorectal cancer, offering effective tumor control and symptom relief for patients who may not be candidates for surgery or other treatments. Transcatheter Arterial Embolization (TAE), also known as Bland Embolization, involves the occlusion of blood vessels supplying the tumor using embolic agents such as microspheres, coils, or particles. TAE is often used as a palliative treatment to relieve symptoms and shrink tumors in patients with advanced cancer, providing symptomatic relief and improving quality of life. These various interventional oncology procedures, including thermal and non-thermal tumor ablation, chemoembolization, radioembolization, and arterial embolization, offer clinicians a diverse toolkit for treating cancer patients with precision and efficacy. As the demand for minimally invasive cancer therapies continues to grow, driven by technological advancements and increasing awareness of their benefits, the market for interventional oncology devices tailored to these procedures is expected to expand significantly in the coming years.
Global Interventional Oncology Devices Market, Segmentation by Cancer Type
In this report, the Global Interventional Oncology Devices Market has been segmented by Cancer Type into Liver Cancer, Kidney Cancer, Lung Cancer, Bone Cancer and Others.
Liver Cancer stands out as one of the primary segments, given the prevalence of hepatocellular carcinoma (HCC) and metastatic liver tumors. Interventional procedures such as transarterial chemoembolization (TACE), radioembolization (TARE), and thermal ablation are commonly employed to treat liver cancer, offering patients effective tumor control and symptom relief. Kidney Cancer represents another significant segment within the interventional oncology devices market, encompassing procedures such as thermal ablation and embolization for renal cell carcinoma (RCC) and metastatic kidney tumors. Minimally invasive techniques allow for precise targeting of tumors within the kidney while preserving healthy tissue, offering patients curative or palliative options depending on disease stage and patient factors.
Lung Cancer is also a notable segment in the interventional oncology devices market, with procedures such as thermal ablation and embolization being utilized for both primary and metastatic lung tumors. These techniques offer patients with lung cancer alternative treatment options, particularly for those who are not candidates for surgery or conventional chemotherapy. Bone Cancer represents another segment, where interventional oncology procedures like thermal ablation and embolization are employed to target bone metastases and primary bone tumors. These procedures aim to alleviate pain, stabilize bone lesions, and improve patient mobility and quality of life.
Global Interventional Oncology Devices Market, Segmentation by Geography
In this report, the Global Interventional Oncology Devices Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Interventional Oncology Devices Market Share (%), by Geographical Region, 2024
North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America, with a forecast period spanning from 2020 to 2030. North America holds a significant share of the market, driven by advanced healthcare systems, high awareness of neurological conditions, and widespread adoption of cutting-edge technologies. The United States, in particular, leads in the use of neurointerventional devices, with a strong emphasis on research, development, and clinical trials for new treatments. Additionally, the region benefits from a large number of well-established hospitals and neurology clinics that facilitate the use of these devices in both emergency and routine care.
Europe also represents a major market for neurointerventional devices, supported by a high prevalence of neurological diseases and a well-developed healthcare infrastructure. Countries like Germany, France, and the United Kingdom are key players, where the adoption of advanced medical technologies is coupled with strong regulatory frameworks. The European market is also benefiting from initiatives aimed at improving access to specialized neurology care and the growing number of diagnostic and therapeutic interventions for conditions like stroke, aneurysms, and other cerebrovascular diseases.
Asia Pacific is expected to see the fastest growth in the market during the forecast period, due to increasing healthcare investments, rising awareness of neurological diseases, and an aging population. Countries such as China, India, and Japan are experiencing significant improvements in healthcare access, which is driving the demand for neurointerventional devices. The Middle East and Africa and Latin America are emerging markets that are gradually adopting neurointerventional technologies, although at a slower pace compared to North America and Europe. However, improving healthcare infrastructure, combined with the growing number of specialized centers and neurology clinics, is expected to drive market expansion in these regions over the coming years.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Interventional Oncology Devices Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunities
Drivers:
- Increasing Incidence of Cancer
- Technological Advancements
-
Growing Preference for Minimally Invasive Procedures: The preference for minimally invasive procedures among patients and healthcare providers stems from their numerous advantages over traditional surgeries. These procedures typically result in shorter recovery times, allowing patients to return to their daily activities more quickly. Reduced hospital stays are also a significant benefit, as patients can often undergo minimally invasive interventions on an outpatient basis or with shorter hospitalization periods, freeing up resources and reducing healthcare costs.
The lower risk of complications associated with minimally invasive techniques is a crucial factor driving their adoption. Compared to open surgeries, which involve larger incisions and more extensive tissue disruption, interventional oncology procedures like radiofrequency ablation and transarterial chemoembolization offer precise targeting of tumors with minimal damage to surrounding healthy tissue. This precision not only reduces the risk of complications but also enhances patient safety and comfort during the treatment process.
The increasing demand for these less invasive alternatives to surgery has spurred the development of related devices tailored to interventional oncology procedures. Manufacturers are investing in technologies that facilitate these techniques, such as specialized ablation devices and advanced imaging systems that enable real-time visualization and precise targeting of tumors. As the benefits of minimally invasive interventions become more widely recognized and as the techniques continue to evolve, the demand for related devices is expected to grow, driving innovation and further improving patient outcomes in the field of interventional oncology.
Restraints:
- High Cost of Interventional Oncology Procedures
- Stringent Regulatory Approval Process
-
Limited Awareness and Accessibility: Limited awareness among both patients and healthcare providers regarding the benefits and availability of interventional oncology procedures poses a significant challenge to market growth. Many individuals may not be familiar with these advanced treatment options or may have misconceptions about their efficacy and safety compared to traditional cancer therapies. As a result, there may be a reluctance among patients to explore interventional oncology procedures as a viable treatment option, leading to underutilization of related devices and technologies. Healthcare providers may also lack sufficient knowledge or training in interventional oncology techniques, leading to under-referral or inappropriate treatment decisions. Addressing this awareness gap requires comprehensive educational initiatives targeting both patients and healthcare professionals. Increasing public awareness through campaigns, informational materials, and patient testimonials can help demystify interventional oncology procedures and highlight their benefits, potentially increasing patient acceptance and demand.
Limited accessibility to advanced healthcare facilities offering interventional oncology services, particularly in rural and remote areas, presents another barrier to market expansion. Patients in these regions may face challenges accessing specialized treatment centers equipped with the necessary expertise and infrastructure to perform interventional oncology procedures. This disparity in healthcare access not only hampers patient outcomes but also limits the market reach of interventional oncology devices. To address this issue, efforts to improve healthcare infrastructure and expand the availability of interventional oncology services to underserved areas are crucial. This may involve investment in telemedicine solutions, mobile healthcare units, or partnerships between urban and rural healthcare facilities to ensure equitable access to these life-saving interventions. By enhancing both awareness and accessibility, the market for interventional oncology devices can overcome these challenges and realize its full growth potential.
Opportunities:
- Emerging Markets
- Expanding Applications
-
Collaborations and Partnerships: Collaborations and partnerships between medical device manufacturers, research institutions, and healthcare providers play a pivotal role in driving innovation and market expansion in the field of interventional oncology. By pooling their expertise, resources, and networks, these entities can collectively address complex challenges, accelerate the development of cutting-edge technologies, and bring novel solutions to market more efficiently.
Research institutions often possess valuable insights into the underlying mechanisms of cancer and emerging treatment modalities. Collaborating with medical device manufacturers allows them to translate these discoveries into practical applications, such as the development of innovative interventional oncology devices and techniques. By leveraging the latest scientific advancements, companies can create products that meet the evolving needs of patients and healthcare providers, driving differentiation and competitive advantage in the market.
Competitive Landscape Analysis
Key players in Global Interventional Oncology Devices Market include
- Boston Scientific Corporation
- Medtronic plc
- Terumo Corporation
- Merit Medical Systems, Inc
- Philips Volcano
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Procedure
- Market Snapshot, By Cancer Type
- Market Snapshot, By Region
- Global Interventional Oncology Devices Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Incidence of Cancer
- Technological Advancements
- Growing Preference for Minimally Invasive Procedures
- Restraints
- High Cost of Interventional Oncology Procedures
- Stringent Regulatory Approval Process
- Limited Awareness and Accessibility
- Opportunties
- Emerging Markets
- Expanding Applications
- Collaborations and Partnerships
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Interventional Oncology Devices Market, By Product, 2021 - 2031 (USD Million)
- Embolization Devices
- Ablation Devices
- Support Devices
- Global Interventional Oncology Devices Market, By Procedure, 2021 - 2031 (USD Million)
- Thermal Tumor Ablation
- Non-thermal Tumor Ablation
- Transcatheter Arterial Chemoembolization (TACE)
- Transcatheter Arterial Radioembolization (TARE) or Selective Internal Radiation Therapy (SIRT)
- Transcatheter Arterial Embolization (TAE) or Bland Embolization
- Global Interventional Oncology Devices Market, By Cancer Type, 2021 - 2031 (USD Million)
- Liver Cancer
- Kidney Cancer
- Lung Cancer
- Bone Cancer
- Others
- Global Interventional Oncology Devices Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Interventional Oncology Devices Market, By Product, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Boston Scientific Corporation
- Medtronic plc
- Terumo Corporation
- Merit Medical Systems, Inc
- Philips Volcano
- Company Profiles
- Analyst Views
- Future Outlook of the Market